Evidence map›Paper›PMID 40467556›Full record

Trial reportNature communications2025

Cytoreductive surgery and hyperthermic intrathoracic chemotherapy in thymic epithelial tumors with pleural spread or recurrence: a prospective, single-arm, phase II study.

Shuai Wang, Xinyu Yang, Jiahao Jiang, Fei Liang, Yuansheng Zheng, Yongqiang Ao, Jian Gao, Hao Wang, Lijie Tan, Jianyong Ding

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Thymic epithelial tumors: what's next?Cancer metastasis reviews · 2026
    Review
  2. Review
  3. Present and future of cytoreductive surgery and hyperthermic intrathoracic chemotherapy for pleural metastases: a narrative review.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuai Wang *Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.ORCID http://orcid.org/0000-0001-8503-9024
Xinyu Yang *Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.ORCID http://orcid.org/0000-0001-9433-667X
Jiahao Jiang *Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.ORCID http://orcid.org/0000-0002-9164-8843
Fei LiangDepartment of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-4184-7844
Yuansheng ZhengDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yongqiang AoDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.ORCID http://orcid.org/0000-0002-0334-0161
Jian GaoDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.ORCID http://orcid.org/0000-0002-6400-7290
Hao WangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Lijie TanDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. tan.lijie@zs-hospital.sh.cn.
Jianyong DingDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. ding.jianyong@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0003-2729-3141

Funding

National Natural Science Foundation of China (National Science Foundation of China) 8240101442National Natural Science Foundation of China (National Science Foundation of China) 82404059
6 · The paper itself

Abstract

Pleural spread or recurrence of thymic epithelial tumors (TETs) is a tricky puzzle in the clinic and there is currently no recognized effective treatment. This trial evaluated the safety and efficacy of cytoreductive surgery and hyperthermic intrathoracic chemotherapy (S-HITOC) for TETs with pleural spread or recurrence. Here, we reported short-term outcomes of enrolled 45 patients receiving S-HITOC with 25 mg/m

Indexed as

Cytoreduction Surgical ProceduresHyperthermia, InducedNeoplasm Recurrence, LocalNeoplasms, Glandular and EpithelialPleural NeoplasmsThymus NeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinCombined Modality TherapyDoxorubicinFemaleHumansMaleMiddle AgedCisplatinDoxorubicin

Identifiers

PMID40467556
PMCPMC12137697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.